Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) Uses, Dosage, Side Effects and more
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection. It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2. These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.
| Trade Name | Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) |
| Generic | Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
